- Poster presentation
- Open Access
Prognostic value of a high level of circulating endothelial cells in patients with HER2-recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxel and gemcitabine as first-line therapy
© Manso et al. 2011
Published: 16 November 2011
Circulating endothelial cells (CECs) are shed from vessels and enter the circulation reflecting endothelial damage. Increased numbers of CECs have been documented in cancer, and appear to correlate with progression of the tumor. Bevacizumab (B) in combination with CT improves progression-free survival (PFS) of first-line treatments and may modify tumor cell intravasation and CEC/CTC levels.
Patients received B (10 mg/kg/2 weeks) combined with paclitaxel (P) 150 mg/m2 and gemcitabine (G) 2,000 mg/m2 days 1 and 15 with a cycle each 28 days of therapy, until disease progression, unacceptable toxicity or withdrawal. CTC/CECs were measured in 7.5 ml blood at baseline and after the first cycle of treatment. Enumeration was performed by the CellSearch System (Veridex).
Our study suggests significant correlations between high levels of baseline CECs and poor prognosis. Addiction of B to first-line CT was related to a high reduction of CEC and CTC count.